SUTRO BIOPHARMA INC's ticker is STRO and the CUSIP is 869367102. A total of 110 filers reported holding SUTRO BIOPHARMA INC in Q3 2023. The put-call ratio across all filers is 1.10 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $6,480,759 | -25.4% | 1,867,654 | 0.0% | 0.01% | -14.3% |
| Q2 2023 | $8,684,591 | +0.6% | 1,867,654 | 0.0% | 0.01% | -12.5% |
| Q1 2023 | $8,628,561 | -42.9% | 1,867,654 | -0.1% | 0.01% | -50.0% |
| Q4 2022 | $15,098,409 | +45.6% | 1,868,615 | 0.0% | 0.02% | +45.5% |
| Q3 2022 | $10,371,000 | +6.7% | 1,868,615 | +0.2% | 0.01% | +10.0% |
| Q2 2022 | $9,717,000 | -36.7% | 1,865,180 | -0.2% | 0.01% | -9.1% |
| Q1 2022 | $15,360,000 | -44.4% | 1,868,501 | +0.7% | 0.01% | -26.7% |
| Q4 2021 | $27,606,000 | -18.6% | 1,855,250 | +3.4% | 0.02% | -16.7% |
| Q3 2021 | $33,906,000 | +1.7% | 1,794,940 | +0.0% | 0.02% | +12.5% |
| Q2 2021 | $33,354,000 | -13.6% | 1,794,173 | +5.8% | 0.02% | -27.3% |
| Q1 2021 | $38,593,000 | +4.8% | 1,695,654 | 0.0% | 0.02% | +10.0% |
| Q4 2020 | $36,813,000 | +116.0% | 1,695,654 | 0.0% | 0.02% | +66.7% |
| Q3 2020 | $17,041,000 | +46.4% | 1,695,654 | +13.0% | 0.01% | +33.3% |
| Q2 2020 | $11,640,000 | – | 1,500,000 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 1,824,542 | $39,611,000 | 19.08% |
| Samsara BioCapital, LLC | 1,675,579 | $36,377,000 | 3.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 185,000 | $4,016,000 | 2.33% |
| Affinity Asset Advisors, LLC | 200,000 | $4,342,000 | 2.30% |
| Altium Capital Management LP | 276,719 | $6,008,000 | 2.24% |
| FRAZIER MANAGEMENT LLC | 1,001,421 | $21,741,000 | 1.67% |
| BVF INC/IL | 1,854,162 | $40,254,000 | 1.58% |
| Asymmetry Capital Management, L.P. | 157,583 | $3,421,000 | 1.56% |
| Parkman Healthcare Partners LLC | 266,645 | $5,789,000 | 1.48% |
| AJU IB Investment Co., Ltd. | 175,000 | $3,799,000 | 1.44% |